

Survival changes in Patients with Synovial Sarcoma, 1983-2012

Shuncong Wang^{1*} M.D., Rongfeng Song^{2*} M.D., Tiantian Sun³ M.D. & Ph.D., Bingzong Hou⁴ M.D. & Ph.D., Guobin Hong⁵ M.D. & Ph.D., Saradhi Mallampati⁶ Ph.D., Hongliu Sun⁷ M.D. & Ph.D., Xiuling Zhou¹ M.D., Cuiling Zhou¹ M.D., Hongyu Zhang¹ M.D. & Ph.D., Zhibin Cheng¹ M.D., Jie Li⁸ M.D. & Ph.D., Haiqing Ma^{1#} M.D. & Ph.D., Huanhuan Sun^{1#} M.D. & Ph.D.

¹Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China;

²Department of Gastroenterology, Cancer Hospital of Jiangxi Province, Nanchang, Jiangxi 330029, China;

³Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China;

⁴Department of Gastrointestinal Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China;

⁵Department of Radiology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China;

⁶Department of Laboratory Medicine and the Center for Stem Cell and Developmental Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;

⁷Department of pathology, University of Michigan, Ann Arbor, MI 48201, USA;

⁸Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.

*These authors contributed equally to this work.

#correspondence to:

Haiqing Ma, M.D. & Ph.D., Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China;
(mahaiqing@mail.sysu.edu.cn) Work Telephone: +86-0756-2528002; FAX:
+86-0756-2528210

or Huanhuan Sun, M.D. & Ph.D., Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China; (huanhuansun10@163.com) Work Telephone: +86-0756-2528888;
FAX: +86-0756-2528210

Supplementary Table S1. Summary data for Cox regression analysis of survival in patients with synovial sarcoma between 1983 and 2012 at 18 SEER sites.

Variable	Hazard Ratio (95% CI)	p-value
All 1983-1992		
Univariate		
Sex	0.762 (0.507 - 1.146)	= 0.192
Age	1.596 (1.355 - 1.880)	< 0.001
Race	1.171 (0.653 - 2.101)	= 0.596
SES	0.918 (0.614 - 1.373)	= 0.678
Stage	3.620 (2.730 - 4.800)	< 0.001
Site	1.303 (0.966 - 1.757)	= 0.083
Pathological type	1.003 (0.775 - 1.297)	= 0.982
Multivariate		
Age	1.519 (1.283 - 1.799)	< 0.001
Stage	3.397 (2.550 - 4.527)	< 0.001
All 1993-2002		
Univariate		
Sex	0.699 (0.551 - 0.886)	= 0.003
Age	1.366 (1.235 - 1.510)	< 0.001
Race	1.421 (1.024 - 1.973)	= 0.036
SES	0.925 (0.732 - 1.168)	= 0.511
Stage	2.952 (2.529 - 3.447)	< 0.001
Site	1.342 (1.179 - 1.527)	< 0.001
Pathological type	0.961 (0.835 - 1.105)	= 0.575
Multivariate		
Sex	0.650 (0.512 - 0.825)	< 0.001
Age	1.310 (1.184 - 1.449)	< 0.001
Stage	2.900 (2.477 - 3.396)	< 0.001
Site	1.160 (1.016 - 1.325)	= 0.028
All 2003-2012		
Univariate		
Sex	0.717 (0.587 - 0.876)	= 0.001
Age	1.507 (1.381 - 1.644)	< 0.001
Race	1.354 (1.027 - 1.785)	= 0.032
SES	1.160 (0.940 - 1.433)	< 0.001
Stage	3.101 (2.734 - 3.517)	< 0.001
Site	1.419 (1.280 - 1.574)	< 0.001
Pathological type	0.762 (0.668 - 0.867)	< 0.001
Multivariate		
Sex	0.865 (0.707 - 1.057)	= 0.157
Age	1.469 (1.342 - 1.607)	< 0.001

SES	1.232 (0.996 - 1.524)	= 0.054
Stage	2.928 (2.571 - 3.334)	< 0.001
Site	1.188 (1.069 - 1.320)	= 0.001
Pathological type	0.867 (0.760 - 0.989)	= 0.034

Abbreviations: 95% CI, 95% confidence interval; SES, socioeconomic status.